Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.56 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.41 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14092828 | 0.95 | CTSB (0.55) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL14116974 | 0.91 | CTSB (0.52) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13409558 | 0.87 | CTSB (0.75) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13409524 | 0.87 | CTSB (0.75) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13409533 | 0.86 | CTSB (0.70) | CTSBPPP3CBCYP3A4 | |
| SCHEMBL3373457 | 0.84 | CYP3A4 (0.42) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13757861 | 0.84 | CYP3A4 (0.42) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL15459234 | 0.83 | CTSB (0.79) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL11947500 | 0.83 | CTSB (0.79) | CTSBPPP3CBABCC1ABCC2ABCG2 | |
| SCHEMBL13409514 | 0.83 | CTSB (0.57) | CTSBPPP3CBABCC1ABCC2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | BAILEY MURRAY D | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200497-A1 | Hepatitis C Inhibitor Peptide Analogs | HAVCR2, ZC3HAV1, CTSC | CTSB 149/4885PPP3CB 234/4885ABCC1 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.